Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.
Commentary|Articles|September 2, 2026
Eichenbaum: KSI-101 could become first-line in uveitic macular edema
Author(s)Kassi Filkins, David A. Eichenbaum, MD, FASRS
Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.
Advertisement
Advertisement
Macular edema secondary to non-infectious inflammation (MESI) remains one of the more difficult presentations in the retina clinic, where treatment still leans heavily on corticosteroids and their well-known cataract and intraocular pressure trade-offs; additionally, no intravitreal biologic is yet FDA-approved specifically for the indication.
Related to this article
Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.
Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.
A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.
A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.
Pivotal wet AMD, DME, and XLRP readouts; the MOGENRY BLA; and Retina Society, EURETINA, and ESCRS highlights from September.
Timothy Janetos, MD, outlined can’t-miss uveitis diagnoses, warning signs, and why every new patient needs dilation.
The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.
Advertisement
Advertisement